Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

IRVINE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, announced the recent publication of a case series of two kidney transplant patients who were monitored for antibody-mediated rejection (AMR) using its proprietary VitaGraft™ Kidney diagnostic test. Patients were tested before, during and after treatment with daratumumab, an anti-CD38 monoclonal antibody¹. The study underscores the significant potential of using repeated VitaGraft Kidney measurements to monitor the efficacy of anti-CD38 therapy.

Read more at globenewswire.com